pharmaceutical investing SELLAS Life Sciences Group and Cancer Center to Study Galinpepimut-S in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma
SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data
SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton for $6.6 Million Payment by JGB
SELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S
SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency
